Downloads

About CombiGene AB

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se

CombiGene AB
Agavägen 52A
SE-181 55 Lidingö
Sweden

info@combigene.com

Logotype – CMYK

(Vector graphic PDF file)

CombiGene logo - CMYK

CombiGene logo neg - CMYK

CombiGene logo green figure neg - CMYK

Logotype – sRGB

(screen graphics)

CombiGene logo - sRGB

CombiGene logo neg - sRGB

CombiGene logo green figure neg - sRGB

About CombiGene AB

Follow what's happening at CombiGene,
subscribe to our newsletter.

Downloads

Logotype – CMYK

(Vector graphic PDF file)

CombiGene logo - CMYK

CombiGene logo neg - CMYK

CombiGene logo green figure neg - CMYK

Logotype – sRGB

(screen graphics)

CombiGene logo - sRGB

CombiGene logo neg - sRGB

CombiGene logo green figure neg - sRGB

About CombiGene AB

Follow what's happening at CombiGene, subscribe to our newsletter.

Follow what's happening at CombiGene,
subscribe to our newsletter.